Industrial Policy & Trade Monitor· 2680 actions· ✨ 93 recent

The Chongqing Municipal People's Government General Office issued "Several Measures for Chongqing's Full-Chain Support of High-Quality Innovative Drug Development" (Yu Fu Ban Fa [2025] No. 56) on 2025-11-01, a 25-point package of regulatory-fast-track and procurement-support measures for the municipal biopharma sector. It targets 1-3 newly approved innovative drugs per year through 2027 (10 total) and the cultivation of 3 pharmaceutical-innovation industrial complexes, 3 high-level innovation platforms, and 3 innovative-drug industry clusters. No direct subsidy or tax-incentive amount is disclosed in the published text — the package is operational (compressed clinical-trial and registration timelines, guaranteed hospital procurement) rather than a cash grant.

On 17 September 2025 the General Office of the Shanghai Municipal People's Government issued Hufubangui [2025] No. 8, a five-year (26 September 2025 - 25 September 2030) state-aid framework to accelerate frontier-technology innovation and cultivate "future industries" across six domains — future manufacturing, future information, future materials, future energy, future space and future health. Targeted technology areas include cell and gene therapy, brain-computer interfaces, biomanufacturing, embodied intelligence (humanoid robotics/AI hardware), fourth-generation semiconductors, silicon photonics, 6G, neuromorphic computing, quantum technology, controlled nuclear fusion and regenerative medicine. Support is disbursed as tiered direct subsidies rather than tax relief, with named ceilings up to CNY 30 million per proof-of-concept/R&D platform and CNY 20 million per high-quality incubator or first-product/batch innovation award.

On 29 August 2025 the Pinggu District (Beijing) Science, Technology and Economic Informatization Bureau issued "Several Measures to Promote the High-Quality Development of High-End Manufacturing in Pinggu District" (平谷区促进高端制造业高质量发展若干措施), published to the district government portal on 25 September 2025 with a two-year validity period. The scheme offers manufacturers registered and operating in Pinggu a stack of output-growth, R&D, smart-factory, green-transformation, pharma/medical- device, auto-parts-supply-chain, and synthetic-biology subsidies, with per-recipient caps ranging from RMB 200,000 up to RMB 10 million for qualifying pharmaceutical/medical-device innovators.

The Hainan Provincial People's Government General Office issued "Several Policy Measures of Hainan Province for Further Supporting High-Quality Development of the Biopharmaceutical Industry" (Qiong Fu Ban [2025] No. 38) on 2025-08-14, effective 2025-09-13 for a three-year term. The package disburses provincial subsidies across the full biopharma value chain — R&D-stage grants, national centralized-procurement awards, international-certification bonuses, platform-investment reimbursement, and traditional-Chinese-medicine insurance-listing awards — leveraging Hainan Free Trade Port status to build a regional biomedical industry cluster.

On 30 April 2025 the General Office of the Guangdong Provincial People's Government issued Yue Fu Ban [2025] No. 11, "Several Measures of Guangdong Province to Further Stimulate Market Entity Vitality and Accelerate the Construction of a Modern Industrial System," effective immediately through 31 December 2027. The package subsidizes bank-loan interest for manufacturing and high-tech enterprises at up to 35% of the loan rate, capped at RMB 2 billion in total annual subsidy volume and RMB 20 million per enterprise per year, alongside an expansion of government-backed financing-guarantee coverage to over RMB 10 billion annually. It also funds foreign-invested R&D centers (up to RMB 1 million, or RMB 5 million for multinational global R&D centers) and offers headquarters-relocation bonuses of up to RMB 8 million, with priority given to semiconductors, AI, robotics, biotechnology, quantum technology, commercial aerospace, and new-energy vehicles.

China's Unreliable Entity List (UEL) Working Mechanism, led by MOFCOM, issued Announcement [2025] No. 2 on 4 February 2025, designating PVH Group (parent of Calvin Klein and Tommy Hilfiger) and Illumina Inc. (US genomics / gene-sequencing equipment maker) as Unreliable Entities under the 2020 UEL Provisions, citing violations of normal market-transaction principles and discriminatory measures against Chinese enterprises. PVH was cited for its Xinjiang-cotton sourcing boycott (MOFCOM probe launched September 2024); Illumina was cited for restricting Chinese customers' access to gene-sequencing equipment. The announcement was issued on the same day as China's IEEPA-retaliation tariff package (10–15 % on US coal, LNG, crude oil, agricultural goods, and autos), making it the first UEL listing of a Western consumer-brand / retail company and the first combining a UEL designation with a subsequent sector-specific export prohibition (gene sequencers, imposed 28 February 2025).